** Shares of Virpax Pharmaceuticals VRPX.O fall 10.4% to 50 cents premarket
** Late on Friday, co disclosed it had received notice on Nov. 19 from Nasdaq about non-compliance with independent director and audit committee rules
** Co says it has appointed Esha Randhawa as an independent director and audit committee member; adds that it has regained compliance with listing rule
** Plans to notify Nasdaq of its compliance - VRPX
** As of last close, stock had fallen 82.3% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。